Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223 dichloride

- PMLiVE

UK government fines GSK over ‘pay-for-delay’ deals

Merck KGaA and Actavis also fined for their involvement

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

How Bayer transformed its approach to digital

Head of digital development Jessica Federer on how the company built digital into its DNA

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

- PMLiVE

Bayer forms JV with gene editing firm CRISPR

$300m investment to find new therapies for blood disorders, blindness and congenital heart disease

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

- PMLiVE

Amgen buys back product rights from GSK

Prolia, Xgeva and Vectibix brought back in-house

- PMLiVE

AZ confirms interest in Acerta takeover

Possible acquisition of Netherlands-based cancer drug developer may be worth more than $5bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links